1. Home
  2. SDGR vs MGTX Comparison

SDGR vs MGTX Comparison

Compare SDGR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$12.15

Market Cap

925.8M

Sector

Health Care

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$9.36

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDGR
MGTX
Founded
1990
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
925.8M
909.1M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
SDGR
MGTX
Price
$12.15
$9.36
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$21.00
$24.57
AVG Volume (30 Days)
1.3M
619.5K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
45.14
33.02
EPS
N/A
N/A
Revenue
$255,869,000.00
$81,391,000.00
Revenue This Year
$0.76
$141.38
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.29
144.57
52 Week Low
$10.95
$5.02
52 Week High
$27.63
$11.85

Technical Indicators

Market Signals
Indicator
SDGR
MGTX
Relative Strength Index (RSI) 47.21 48.12
Support Level $11.18 $7.13
Resistance Level $13.36 $9.65
Average True Range (ATR) 0.65 0.48
MACD -0.06 -0.07
Stochastic Oscillator 32.53 42.57

Price Performance

Historical Comparison
SDGR
MGTX

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: